Dehydroxyfluorafinil

Dehydroxyfluorafinil, often called Modafiendz, attracts interest as a modafinil-related wakefulness compound. Reports include easier focus, unpleasant stimulation, no benefit and palpitations. These accounts do not establish effectiveness or safety.

What it is and why people discuss it

• A distinct modafinil-related molecule. Dehydroxyfluorafinil is the compound also called Modafiendz or N-methyl-4,4-difluoromodafinil (CAS 1613222-54-0). It differs chemically from modafinil, flmodafinil and fladrafinil; reports about those relatives cannot establish its effects. Official context Official context
• The attraction is usable alertness. The Drug Users Bible author described less drowsiness and greater sharpness, but found the experience distinctly drug-like. Staying awake and enjoying the experience were separate outcomes. Personal report

Benefits and comparisons people report

• One person’s focus comparison. After an initially ineffective 25 mg trial, boselect compared 100 mg with 200 mg modafinil for focus, with slightly less wakefulness. This is one person’s comparison, not a conversion rule. Bluelight
• Armodafinil felt smoother to one author. The Drug Users Bible account preferred armodafinil and would not repeat Modafiendz despite reduced sleepiness. That personal comparison cannot rank the compounds’ safety. Personal report

Doses people discuss

• 100 mg oral pill: one author’s maximum experienced. The Drug Users Bible records this maximum, not a daily regimen. Its separate TripSit-attributed chart says light 50 mg+, common 100 mg+ and strong 100 mg+; those overlapping labels do not define a validated range. Personal report
• 25 mg, then 75 mg: a null/tiredness account. cornishninja described a quarter-tablet estimate followed by a later 75 mg trial. These were separate administrations. The poster sought relief from next-day sedative tiredness but did not specify prior-night exposure. Bluelight
• 25–200+ mg appears in a circulated oral chart. PsychonautWiki labels 25 mg threshold, 50–100 mg light, 100–150 mg common, 150–200 mg strong and 200 mg+ heavy. Those labels describe an unsourced community chart, not measured prevalence or a safe escalation ladder. Community guide

Half-life

• No reliable compound-specific human estimate found. The inspected reports do not measure elimination. The circulated duration figure below cannot tell us when half the substance has left the body, and modafinil’s half-life should not be borrowed. Bluelight Community guide

When people notice it

• Useful-effect onset remains unclear. Rybee placed unwanted palpitations at about 30 minutes. That adverse-effect timing does not establish when focus or wakefulness should begin. Bluelight

How long people feel it

• 5–8 hours is a community-summary claim. PsychonautWiki gives this total duration without an identifiable underlying log or measurement. Treat it as circulated timing, not predictable coverage or clearance. Community guide
• Morning-to-evening alertness in one report. Chips described a calm, awake evening after morning use but supplied neither an amount nor clock times. The account cannot resolve a precise duration. Bluelight

Repeated use and breaks

• No well-supported cycle or tolerance reset. PsychonautWiki repeats 3–7 days for tolerance to halve and 1–2 weeks to return to baseline, marking both as needing citation. These are not a validated break schedule; the inspected personal reports do not establish a reproducible cycle. Community guide

What can outweigh the benefit

• Repeated palpitations with no useful effect. Rybee reported prolonged palpitations on three 100 mg occasions, with a prior history of palpitations. Earlier caffeine/exercise explanations and unverified tablets limit causation; the repetition remains concerning. Bluelight
• Severe anxiety occurred in a mixed-drug episode. Denzil described 100 mg Modafiendz (route unstated), then 10 mg intranasal ethylphenidate after etizolam, alcohol and disrupted sleep. Anxiety worsened, with cognitive fog and tremor; pre-existing symptoms and co-use prevent assigning the episode to Modafiendz alone. Personal report
• Sweating and muscle tension can rise without added benefit. Chips reported that tradeoff above an unspecified amount. A favorable initial response did not mean that more improved the experience. Bluelight
• Long-term safety and interactions remain poorly characterized. Cayman’s reference document explicitly describes unknown physiological and toxicological properties. Neither quiet stimulation nor chemical similarity to modafinil establishes predictable interactions or safety. Official context

What the formal research can tell us

• Chemical identification is not a benefit trial. The inspected laboratory paper characterizes these compounds and shows how heating during chemical analysis can produce misleading results. It does not establish human effectiveness, dosing or half-life for dehydroxyfluorafinil. Official context

What the community accounts add

• A negative report is not always simple nonresponse. cornishninja reported falling asleep and later feeling tired, while Chips liked the alertness and music enjoyment. Their differing circumstances do not establish a responder profile. Bluelight
• The adverse stack report changed over time. By November 23, 2014, Denzil reported less anxiety but persistent loss of pleasure. Later posts described some return to activity alongside continuing symptoms, medication changes and kratom; the final February 5, 2015 update still involved psychiatric care. This establishes neither neurological injury nor full recovery. Personal report Personal report
• Secondhand side effects need their own label. The Drug Users Bible author mentions online reports of jitters and vasoconstriction. Those are secondhand observations, distinct from the author’s own unpleasant stimulation. Personal report